About
About Innovative Pharmaceutical Biotech Limited
Starcoin Group Limited, an investment holding company, engages in the trading of beauty products in the People's Republic of China and Hong Kong. It operates in two segments, Trading of Beauty Products, and Research and Development. The company is also involved in the research, development, and commercialization of oral insulin products; and the provision of genetic testing services, as well as securities investment. In addition, it offers healthcare management and bio-industrial products distribution services. The company has a strategic cooperation agreement with Huamei Haibo Biotechnology (Chongqing) Co., Ltd for development in the biotechnology and healthcare sectors. The company was formerly known as Innovative Pharmaceutical Biotech Limited and changed its name to Starcoin Group Limited in August 2025. Starcoin Group Limited was incorporated in 2000 and is based in Central, Hong Kong.
Visit company website
5 years, 4 months ago
Innovative Pharmaceutical Biotech Limited is currently in a long term downtrend where the price is trading 1.2% below its 200 day moving average.
From a valuation standpoint, the stock is 1047.1% more expensive than other stocks from the Consumer Defensive sector with a price to sales ratio of 34.4.
Innovative Pharmaceutical Biotech Limited's total revenue sank by 35.7% to $7M since the same quarter in the previous year.
Its net income has increased by 15.4% to $-93M since the same quarter in the previous year.
Finally, its free cash flow fell by 22.8% to $-9M since the same quarter in the previous year.
Based on the above factors, Innovative Pharmaceutical Biotech Limited gets an overall score of 1/5.